NEWSROOM

Stay current with MiRXES

Featured

Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market. – from Singapore to the world.

22 November 2021

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

15 November 2021

MiRXES announced today the appointment of Mr. Dan HEADON as Senior Vice President (SVP), Marketing. Mr. Headon will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products. 

23 October 2021

Yayasan MENDAKI and MiRXES , are pleased to announce today the setting up of the “MENDAKI – MIRXES Scholarship” for Malay/Muslim students who are pursuing undergraduate and post-graduate studies in Life and Biomedical Sciences. In addition to the scholarships, the students will also receive internship opportunities and securing employment opportunities with MiRXES upon their graduation.

1 October 2021

MiRXES announced today   the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products. 

21 September 2021

MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.

20 September 2021

MiRXES announced today the appointment of Dr. David CAPES as Senior Vice President and Global Head of Innovation. In this newly created role, Dr. Capes will focus on the transformation of MIRXES from a regional SME to a global innovation enterprise over the next three years

Dr Holger Heyn

28 July 2021

Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics

PCR Lab

8 July 2021

This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare

24 February 2021

This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.

Media Coverage

Stay informed and keep abreast with our media news.

15 November 2021

The Peak – Imagine this: you walk into a clinic for an early detection test that identifies biomarkers in your blood to detect potentially life-threatening diseases in their early stages when they are still asymptomatic. In the stylish waiting room, you nibble on a croissant and sip a latte. You almost feel like you are at a spa, not a medical clinic.

23 Oct 2021

Berita Mediacorp – Penuntut Melayu/Islam dalam bidang Sains Hayat dan Bioperubatan kini mendapat satu lagi sokongan serta peluang pekerjaan dalam bidang itu, hasil biasiswa yang dilancarkan hari ini (23 Okt) oleh Yayasan MENDAKI dan syarikat bioteknologi MirXES. Bernilai S$140,000 kesemuanya, Biasiswa MENDAKI-MiRXES itu juga menawarkan peluang latihan industri (internship) dan bekerja dengan syarikat itu setelah tamat pengajian.

Collaborations

Our partnerships

15 Sep 2021

ヒューマン・メタボローム・テクノロジーズ株式会社
代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。

31 Aug 2021

大阪国際がんセンター(以下、当センター)は、希少疾患の一つである成人T細胞白血病リンパ腫※1(以下、ATL)のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。

Insights

Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.

As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.

Media and Investor Contact

For media enquiries, please email: communications@mirxes.com

Copyright © 2021 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top